Fresenius Medical Care AG & Co. KGaA (FMS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
FMS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
FMS Revenue Analysis (2014–2025)
As of March 2, 2026, Fresenius Medical Care AG & Co. KGaA (FMS) generated trailing twelve-month (TTM) revenue of $19.63 billion, reflecting slight decline in growth of -0.3% year-over-year. The most recent quarter (Q4 2025) recorded $5.07 billion in revenue, up 3.8% sequentially.
Looking at the longer-term picture, FMS's 5-year compound annual growth rate (CAGR) stands at +1.9%, indicating moderate growth over time. The company achieved its highest annual revenue of $19.63 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows FMS's business is primarily driven by Health Care Services (75%), and Health Care Products (25%). With over half of revenue concentrated in Health Care Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DVA (+6.5% YoY), TOI (+21.7% YoY), and CCM (-22.5% YoY), FMS has underperformed the peer group in terms of revenue growth. Compare FMS vs DVA →
Peer Comparison
Compare FMS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FMSCurrent | $19.6B | -0.3% | +1.9% | 9.3% | |
| DVA | $13.6B | +6.5% | +3.4% | 14.7% | |
| TOI | $393M | +21.7% | +20.4% | -15.3% | |
| CCM | $384M | -22.5% | +14.1% | -138.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $19.63B | +1.5% | $5.03B | 25.6% | $1.83B | 9.3% |
| 2024 | $19.34B | -0.6% | $4.76B | 24.6% | $1.39B | 7.2% |
| 2023 | $19.45B | +0.3% | $4.93B | 25.3% | $1.37B | 7.0% |
| 2022 | $19.40B | +10.1% | $4.89B | 25.2% | $1.51B | 7.8% |
| 2021 | $17.62B | -1.3% | $4.77B | 27.1% | $1.85B | 10.5% |
| 2020 | $17.86B | +2.2% | $5.54B | 31.0% | $2.30B | 12.9% |
| 2019 | $17.48B | +5.6% | $5.40B | 30.9% | $2.27B | 13.0% |
| 2018 | $16.55B | -7.0% | $5.16B | 31.2% | $3.04B | 18.4% |
| 2017 | $17.78B | +4.4% | $6.00B | 33.8% | $2.36B | 13.3% |
| 2016 | $17.03B | +11.2% | $5.50B | 32.3% | $2.51B | 14.7% |
See FMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FMS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FMS vs AGIO
See how FMS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FMS's revenue growth accelerating or slowing?
FMS revenue growth slowed to -0.3%, below the 5-year CAGR of +1.9%. TTM revenue is $19.6B. The deceleration marks a shift from historical growth rates.
What is FMS's long-term revenue growth rate?
Fresenius Medical Care AG & Co. KGaA's 5-year revenue CAGR of +1.9% reflects the variable expansion pattern. Current YoY growth of -0.3% is near this long-term average.
How is FMS's revenue distributed by segment?
FMS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.